Screening for viral markers in volunteer and replacement blood donors in West Africa

被引:81
作者
Sarkodie, F
Adarkwa, M
Adu-Sarkodie, Y
Candotti, D
Acheampong, JW
Allain, JP
机构
[1] Natl Blood Serv, E Anglia Blood Ctr, Dept Haematol, Div Transfus Med, Cambridge CB2 2PT, England
[2] Komfo Anokye Teaching Hosp, Dept Med, Blood Serv, Kumasi, Ghana
[3] Komfo Anokye Teaching Hosp, Dept Microbiol, Kumasi, Ghana
[4] Univ Cambridge, Dept Haematol, Div Transfus Med, Cambridge, England
关键词
blood screening; HBV; HCV; HIV; West Africa;
D O I
10.1046/j.1423-0410.2001.00023.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives West Africa is a highly endemic area for viral infections. The prevalence of five viral markers was determined in Ghanaian blood donors. Materials and Methods Replacement and volunteer blood donors were screened using enzyme immunoassays (EIAs) for hepatitis B surface antigen (HBsAg), human immunodeficiency virus antibodies (anti-HIV), HIV p24 antigen, human T-cell lymphocytotrophic virus-I and -II antibodies (anti-HTLV-I/II) and hepatitis C virus antibodies (anti-HCV). Results HBsAg was present at an equally high frequency (15%) in young volunteer (median age 18 years) and older replacement (median age 33 years) blood donors. In contrast, the prevalence of anti-HIV and anti-HCV was significantly higher in replacement blood donors (24 and 0.3%, respectively, P < 0.001). HCV RNA was detected in 74 or 55% of seropositive donors, depending on the confirmatory criteria used. No p24 antigen-positive/anti-HIV-negative donations were found. The prevalence of HTLV-I/II was generally low (0.5%). Conclusion All blood donations should be screened for hepatitis B virus (HBV), HIV and HCV markers.
引用
收藏
页码:142 / 147
页数:6
相关论文
共 29 条
[1]  
ADARKWA M, 2000, 26 C INT SOC BLOOD T
[2]   Safety and efficacy of hepatitis C virus antibody screening of blood donors with two sequential screening assays [J].
Allain, JP ;
Kitchen, A ;
Aloysius, S ;
Reeves, I ;
Petrik, J ;
Barbara, JAJ ;
Williamson, LM .
TRANSFUSION, 1996, 36 (05) :401-405
[3]  
ALLAIN JP, 1996, TRANSFUSION, V36, P339
[4]   HUMAN-IMMUNODEFICIENCY-VIRUS ANTIGENEMIA IN PATIENTS WITH AIDS AND AIDS-RELATED DISORDERS - A COMPARISON BETWEEN EUROPEAN AND CENTRAL AFRICAN POPULATIONS [J].
BAILLOU, A ;
BARIN, F ;
ALLAIN, JP ;
PETAT, E ;
KOCHELEFF, P ;
KADENDE, P ;
GOUDEAU, A .
JOURNAL OF INFECTIOUS DISEASES, 1987, 156 (05) :830-833
[5]   Seroprevalence of hepatitis B and C, and human immunodeficiency type 1 viruses in a rural population from the Republic of Equatorial Guinea [J].
Basaras, M ;
Santamaría, A ;
Sarsa, M ;
Gutiérrez, E ;
de Olano, Y ;
Cisterna, R .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1999, 93 (03) :250-252
[6]   2ND-GENERATION HEPATITIS-C VIRUS ASSAYS - PERFORMANCE WHEN TESTING AFRICAN SERA [J].
CALLAHAN, JD ;
CONSTANTINE, NT ;
KATAAHA, P ;
ZHANG, X ;
HYAMS, KC ;
BANSAL, J .
JOURNAL OF MEDICAL VIROLOGY, 1993, 41 (01) :35-38
[7]  
CANDOTTI D, 2000, 26 C INT SOC BLOOD T
[8]  
Chikwem JO, 1997, E AFR MED J, V74, P213
[9]   The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt [J].
Frank, C ;
Mohamed, MK ;
Strickland, GT ;
Lavanchy, D ;
Arthur, RR ;
Magder, LS ;
El Khoby, T ;
Abdel-Wahab, Y ;
Ohn, EA ;
Anwar, W ;
Sallam, I .
LANCET, 2000, 355 (9207) :887-891
[10]  
JACOBS B, 1994, E AFR MED J, V71, P720